The treatment of cancer involves different strategies, such as chemotherapy, surgery, radiation therapy and, most recently, targeted therapies, such as the use of radionuclide-based therapies employed ...

The Pb-212-based radionuclide treatment, dubbed ADVC001, is currently undergoing a phase 1/2 dose-escalation trial in metastatic prostate cancer. AdvanCell’s hope is that ADVC001 will prove ...

Ariceum Therapeutics (Ariceum), a private biotech company developing radiopharmaceutical products for the diagnosis and treatment of certain hard-to-treat cancers, today announced that the U.S. Food ...

Bayer has agreed to buy Noria Therapeutics and its subsidiary PSMA Therapeutics, adding to its pipeline of radionuclide drugs for cancer as sales of its lead product in the category – Xofigo ...

Radionuclide therapy is changing dynamically. Monoclonal antibody therapies for non-Hodgkins lymphoma using iodine-131; or imaging with indium-111, followed with yttrium-90 for the therapy are the ...

PRRT is a possible treatment for some NETs that start in the pancreas or the digestive system. It is not a treatment for NECs. Radioisotope therapy uses radioactive medicines to treat some cancer ...

AdvanCell is developing therapies to treat cancers including: prostate, skin, pancreatic, breast, bladder, colorectal, kidney ...

Decommissioning, Decontamination, and Technique Development During nuclear decommissioning, radionuclide contaminated materials need to be accurately identified and sentenced for disposal as ...

This investment will fuel AdvanCell’s ongoing efforts to expand its manufacturing capacity, accelerate the clinical development of its pipeline of radionuclide therapies, and advance its mission ...

This study utilizes bibliometric analysis to investigate the research landscape of FAP-directed cancer theranostics, focusing ...

AdvanCell, a clinical-stage radiopharmaceutical company specializing in targeted alpha therapies, is expanding the scope and ...